You are currently browsing the archives for 13 February 2018.
Displaying 1 - 2 of 2 entries.

It neglected the problem of fragile societies.

To find out more on Loyola University Health System, log onto.. British PM Cameron should keep development aid pledge The Millennium Advancement Goals program ‘appeared for too quick a fix. Above all, it neglected the problem of fragile societies, placing the cart of poverty reduction, disease eradication and the like prior to the horse of great governance. And it didn’t recognize that adding to the sum of resources in conflict-prone societies can have got the result of increasing internal conflicts instead of reducing them,’ a Guardian editorial states. However, with a fresh ‘widespread recognition of the faults and of the necessity for new approaches,’ British Prime Minister David Cameron ‘should adhere to his guns’ with his pledge to increase development aid, even if it’s unpopular with voters, the editorial concludes .

A clinical-stage biopharmaceutical business with a focus on cardiovascular disease.

Amarin completes patient randomization in AMR101 Stage 3 trial in sufferers with high triglyceride levels Amarin Corporation plc , a clinical-stage biopharmaceutical business with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. THE BUSINESS indicated that it anticipates reporting top-line results from this trial in Q2 2011 http://www.montfordpharmacy.com . The ANCHOR trial can be a multi-center, placebo-managed, randomized, double-blind, 12-week pivotal research to evaluate the efficacy and basic safety of 2 grams and 4 grams of AMR101 in sufferers with high triglyceride amounts from 200 mg/dL to less than 500 mg/dL who are also on statin therapy.